Please Note:

The Open Access Repository has moved to a new authentication system as of the 1st of November.

Account holders will now be able to login using their University of Tasmania credentials.
If you have trouble logging in please email us on E.Prints@utas.edu.au so we can assist you.

Public users can still access the records in this repository as normal

Open Access Repository

Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome

Downloads

Downloads per month over past year

Ding, C (2006) Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome. Current Opinion in Investigational Drugs, 7 (11). pp. 1020-1025. ISSN 1472-4472

[img]
Preview
PDF
vx-702.pdf | Download (221kB)
Available under University of Tasmania Standard License.

| Preview

Abstract

Vertex Pharmaceuticals Inc, in collaboration with Kissei
Pharmaceutical Co Ltd, is developing VX-702, one of a series of second-generation, orally active p38 MAP kinase inhibitors, for the potential treatment of inflammation, rheumatoid arthritis and cardiovascular diseases. In June 2005, a phase II clinical trial of VX-702 was initiated in rheumatoid arthritis. In July 2006, Vertex was planning to file an IND in the second half of 2006.

Item Type: Article
Journal or Publication Title: Current Opinion in Investigational Drugs
Page Range: pp. 1020-1025
ISSN: 1472-4472
Additional Information:

restricted - published by Thompson

Date Deposited: 28 Mar 2008 00:47
Last Modified: 18 Nov 2014 03:32
Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page
TOP